Bruker's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bruker's ROA in the third quarter of 2026?
Bruker Corporation recorded a cumulative net loss of $-118 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -1.75%.

However, within the Healthcare sector 231 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 2582, from total ROA ranking in the second quarter of 2026 at 2964.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	-2.17 %	5.18 %	3.33 %	34.14 %	5.27 %
Y / Y Net Income Change	-	-	-6.55 %	110.07 %	-
Net Income (TTM) in million	-118	-65	-9	-8	-24
Return On Assets (TTM)	-1.75 %	-0.95 %	-0.14 %	-0.13 %	-0.39 %
BRKR's Total Ranking	# 2582	# 2964	# 2632	# 2069	# 2033
Total Assets (TTM) in million	6,295	6,668	6,131	7,793	6,435
Seq. Total Assets Change	-5.6 %	8.77 %	-21.33 %	21.11 %	1.5 %
Seq. Net Income Change	-	-	-46.23 %	-	-

BRKR's 5 Years Annual ROA >> Back to BRKR Management Effectiveness >> Compare BRKR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 10
Sector	# 232
Overall	# 2744

Return On Assets Statistics
High	Average	Low
10.92 %	5.75 %	-1.94 %
(Dec 31 2023)		(Sep 30 2026)

Financial Statements
Bruker's Assets	$ 6,295 million	BRKR's Balance sheet
Bruker's Income	$ -112 million	Quarterly BRKR's Income Statement
BRKR's Income by Division		See BRKR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	7.49 %	36.63 %	17.67 %	-1.05 %	15.89 %
Total Assets in million	6,241	5,807	4,250	3,612	3,650
Y / Y Net Income Change	-	-73.44 %	43.55 %	6.38 %	73.85 %
Net Income in million	-8	114	429	299	281
Annual Return On Assets	-0.13 %	1.96 %	10.08 %	8.26 %	7.69 %

BRKR's 5 Years Annual ROA >> Back to BRKR Management Effectiveness >> Compare BRKR ROA to its Competitors

More Return On Assets Ratios
BRKR's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BRKR's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BRKR's Competitors
Subscribers only: Roa for Bruker's Suppliers
Subscribers only: Return On Assets for BRKR's Customers

You may also want to know
BRKR's Roi	BRKR's Inventory Turnover Ratio	BRKR's Growth Rates	BRKR's Dividend Comparisons
	BRKR's Profitability Ratios	BRKR's Asset Turnover Ratio	BRKR's Dividend Growth
BRKR's Roe	BRKR's Valuation Ratios	BRKR's Financial Strength Ratios	BRKR's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-08T19:12:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.